A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer

R. Rosell, A. Abad‐Esteve, I. Moreno, A. Barnadas, J. Carles, C. Fernandez, N. Ribelles, M. Culubret

Producció científica: Contribució a una revistaArticleRecercaAvaluat per experts

31 Cites (Scopus)

Resum

The current trial was carried out to assess the survival enhancement achieved, if any, by adding ifosfamide to vindesine and cisplatin (IVP) in contrast to mitomycin plus vindesine and cisplatin (MVP). Between June 1986 and September 1988, 110 patients were randomly allocated to receive either ifosfamide (3 g/m2 plus 3 g/m2 of mesna) or mitomycin 8 mg/m2, on days 1, 29, and 71 only. In both arms vindesine was given 3 mg/m2 weekly X 5 then every 2 weeks. In the MVP arm, 120 mg/m2 of cisplatin was administered on days 1 and 29 and then every 6 weeks, whereas in the IVP arm 100 mg/m2 of cisplatin was given on the same time schedule. One hundred three patients were evaluable for response and toxicity and 56% of patients had Mountain's Stage IV disease. The response rate was 26% (14/53 patients) in the MVP arm (95% confidence interval, 14%‐39%) and 20% (ten of 50 patients) in the IVP arm (95% confidence interval, 10%‐34%). Neither the response rate nor the median survival times were significantly different, although more nephrotoxicity was produced in the MVP arm, grade 1+ in 43% versus 26% in IVP arm (P = 0.04). Results obtained from this study fail to demonstrate that mitomycin or ifosfamide have a synergistic effect on the efficacy of the vindesine/cisplatin combination. Copyright © 1990 American Cancer Society
Idioma originalEnglish
Pàgines (de-a)1692-1699
RevistaCancer
Volum65
Número8
DOIs
Estat de la publicacióPublicada - 1 de gen. 1990

Fingerprint

Navegar pels temes de recerca de 'A randomized study of two vindesine plus cisplatin‐containing regimens with the addition of mitomycin C or ifosfamide in patients with advanced non‐small cell lung cancer'. Junts formen un fingerprint únic.

Com citar-ho